Patient characteristics
| . | n = 3759 . |
|---|---|
| Median age at HCT, y (range) | 50 (16-74) |
| Age, category | |
| <50 | 1807 (48.1) |
| ≥50 | 1952 (51.9) |
| Sex match between recipient and donor | |
| Female recipient or male to male | 3004 (79.9) |
| Female to male | 755 (20.1) |
| Recipient/donor CMV serostatus | |
| Negative/positive | 352 (9.4) |
| Positive/negative | 1406 (37.4) |
| Positive/positive | 2001 (53.2) |
| Letermovir prophylaxis | |
| No | 3484 (92.7) |
| Yes | 275 (7.3) |
| Disease | |
| AML | 1400 (37.2) |
| ALL | 917 (24.4) |
| MDS | 784 (20.9) |
| CML | 158 (4.2) |
| ATL | 179 (4.8) |
| NHL | 197 (5.2) |
| MPN | 124 (3.3) |
| DRI | |
| Low | 290 (7.7) |
| Intermediate | 2779 (73.9) |
| High | 690 (18.4) |
| KPS | |
| >80% | 3257 (86.7) |
| ≤80% | 502 (13.4) |
| HCT-CI | |
| <2 | 2838 (75.5) |
| ≥2 | 921 (24.5) |
| Donor source | |
| HLA matched related | 797 (21.2) |
| HLA 1-antigen-mismatched related | 108 (2.9) |
| HLA matched unrelated | 1049 (27.9) |
| HLA 1-locus-mismatched unrelated | 1147 (30.5) |
| Umbilical cord blood | 446 (11.9) |
| Haploidentical | 212 (5.6) |
| Conditioning intensity | |
| Myeloablative | 2624 (69.8) |
| Reduced intensity | 1135 (30.2) |
| GVHD prophylaxis | |
| MTX and CNI | 3190 (84.9) |
| MMF and CNI | 405 (10.8) |
| Other | 164 (4.4) |
| In vivo T-cell depletion | |
| No | 3430 (91.3) |
| Yes | 329 (8.8) |
| Year of HCT | |
| 2008-2013 | 1818 (48.4) |
| 2014-2019 | 1941 (51.6) |
| Organ involvement at the development of grade II-IV acute GVHD | |
| Skin GVHD | |
| No | 929 (24.7) |
| Yes | 2830 (75.3) |
| Lower-gut GVHD | |
| No | 1980 (52.7) |
| Yes | 1779 (47.3) |
| Liver GVHD | |
| No | 3504 (93.2) |
| Yes | 255 (6.8) |
| Use of systemic steroids | |
| No | 753 (20.0) |
| Yes | 3006 (80.0) |
| . | n = 3759 . |
|---|---|
| Median age at HCT, y (range) | 50 (16-74) |
| Age, category | |
| <50 | 1807 (48.1) |
| ≥50 | 1952 (51.9) |
| Sex match between recipient and donor | |
| Female recipient or male to male | 3004 (79.9) |
| Female to male | 755 (20.1) |
| Recipient/donor CMV serostatus | |
| Negative/positive | 352 (9.4) |
| Positive/negative | 1406 (37.4) |
| Positive/positive | 2001 (53.2) |
| Letermovir prophylaxis | |
| No | 3484 (92.7) |
| Yes | 275 (7.3) |
| Disease | |
| AML | 1400 (37.2) |
| ALL | 917 (24.4) |
| MDS | 784 (20.9) |
| CML | 158 (4.2) |
| ATL | 179 (4.8) |
| NHL | 197 (5.2) |
| MPN | 124 (3.3) |
| DRI | |
| Low | 290 (7.7) |
| Intermediate | 2779 (73.9) |
| High | 690 (18.4) |
| KPS | |
| >80% | 3257 (86.7) |
| ≤80% | 502 (13.4) |
| HCT-CI | |
| <2 | 2838 (75.5) |
| ≥2 | 921 (24.5) |
| Donor source | |
| HLA matched related | 797 (21.2) |
| HLA 1-antigen-mismatched related | 108 (2.9) |
| HLA matched unrelated | 1049 (27.9) |
| HLA 1-locus-mismatched unrelated | 1147 (30.5) |
| Umbilical cord blood | 446 (11.9) |
| Haploidentical | 212 (5.6) |
| Conditioning intensity | |
| Myeloablative | 2624 (69.8) |
| Reduced intensity | 1135 (30.2) |
| GVHD prophylaxis | |
| MTX and CNI | 3190 (84.9) |
| MMF and CNI | 405 (10.8) |
| Other | 164 (4.4) |
| In vivo T-cell depletion | |
| No | 3430 (91.3) |
| Yes | 329 (8.8) |
| Year of HCT | |
| 2008-2013 | 1818 (48.4) |
| 2014-2019 | 1941 (51.6) |
| Organ involvement at the development of grade II-IV acute GVHD | |
| Skin GVHD | |
| No | 929 (24.7) |
| Yes | 2830 (75.3) |
| Lower-gut GVHD | |
| No | 1980 (52.7) |
| Yes | 1779 (47.3) |
| Liver GVHD | |
| No | 3504 (93.2) |
| Yes | 255 (6.8) |
| Use of systemic steroids | |
| No | 753 (20.0) |
| Yes | 3006 (80.0) |
CNI, calcineurin inhibitor; MTX, methotrexate.